NASDAQ:DRRX - DURECT News Headlines

Sign in or create an account to add this stock to your watchlist.
$0.73 -0.05 (-6.41 %)
(As of 02/21/2019 04:21 AM ET)
Previous Close$0.78
Today's Range$0.72 - $0.79
52-Week Range$0.46 - $2.55
Volume463,900 shs
Average Volume386,656 shs
Market Capitalization$118.30 million
P/E Ratio-24.33
Dividend YieldN/A
Beta1.82

Headlines

DURECT (NASDAQ DRRX) News Headlines

Source:
DateHeadline
Global Pain Therapeutics Market Report 2019: Market Trends & R&D Insights 2017-2023 - GlobeNewswireGlobal Pain Therapeutics Market Report 2019: Market Trends & R&D Insights 2017-2023 - GlobeNewswire
globenewswire.com - February 20 at 8:34 AM
 Analysts Anticipate DURECT Co. (DRRX) Will Post Quarterly Sales of $3.65 Million Analysts Anticipate DURECT Co. (DRRX) Will Post Quarterly Sales of $3.65 Million
www.americanbankingnews.com - February 10 at 4:56 AM
 Analysts Expect DURECT Co. (DRRX) to Post -$0.05 Earnings Per Share Analysts Expect DURECT Co. (DRRX) to Post -$0.05 Earnings Per Share
www.americanbankingnews.com - February 8 at 3:22 AM
Clementia Pharmaceuticals (CMTA) & DURECT (DRRX) Financial ComparisonClementia Pharmaceuticals (CMTA) & DURECT (DRRX) Financial Comparison
www.americanbankingnews.com - February 3 at 3:06 AM
DURECT Corporation Provides Corporate UpdateDURECT Corporation Provides Corporate Update
finance.yahoo.com - January 7 at 8:20 AM
Here’s What We Think About DURECT Corporation’s (NASDAQ:DRRX) CEO PayHere’s What We Think About DURECT Corporation’s (NASDAQ:DRRX) CEO Pay
finance.yahoo.com - January 4 at 5:40 PM
DURECT Corporation Announces Investor Call to Provide Corporate UpdateDURECT Corporation Announces Investor Call to Provide Corporate Update
finance.yahoo.com - January 4 at 8:14 AM
Commercial Launch Plans Announced for PERSERIS™ (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in AdultsCommercial Launch Plans Announced for PERSERIS™ (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults
finance.yahoo.com - December 19 at 8:26 AM
Durect tweaks protocol of mid-stage study of DUR-928 to accelerate dosing of severe AH patientsDurect tweaks protocol of mid-stage study of DUR-928 to accelerate dosing of severe AH patients
seekingalpha.com - November 19 at 5:18 PM
DURECT Announces Amendment to Accelerate Ongoing Phase 2a Trial of DUR-928 in Alcoholic Hepatitis (AH) by Allowing Dosing of Severe AH Patients in Parallel to Moderate AH PatientsDURECT Announces Amendment to Accelerate Ongoing Phase 2a Trial of DUR-928 in Alcoholic Hepatitis (AH) by Allowing Dosing of Severe AH Patients in Parallel to Moderate AH Patients
finance.yahoo.com - November 19 at 8:22 AM
DRRX: Protocol Amendment Speeds DUR-928 Ph2 AH Trial. PERSERIS FDA Approval Adds New Revenue StreamDRRX: Protocol Amendment Speeds DUR-928 Ph2 AH Trial. PERSERIS FDA Approval Adds New Revenue Stream
finance.yahoo.com - November 16 at 5:50 PM
Could DURECT Corporation’s (NASDAQ:DRRX) Investor Composition Influence The Stock Price?Could DURECT Corporation’s (NASDAQ:DRRX) Investor Composition Influence The Stock Price?
finance.yahoo.com - November 13 at 5:08 PM
Edited Transcript of DRRX earnings conference call or presentation 7-Nov-18 9:30pm GMTEdited Transcript of DRRX earnings conference call or presentation 7-Nov-18 9:30pm GMT
finance.yahoo.com - November 9 at 8:28 AM
Durect Corporation (DRRX) CEO James Brown on Q3 2018 Results - Earnings Call TranscriptDurect Corporation (DRRX) CEO James Brown on Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - November 8 at 8:27 AM
Durect EPS in-line, misses on revenueDurect EPS in-line, misses on revenue
seekingalpha.com - November 7 at 5:42 PM
DURECT Corporation Announces Third Quarter 2018 Financial Results and Provides Corporate UpdateDURECT Corporation Announces Third Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - November 7 at 5:42 PM
Durect: 3Q Earnings SnapshotDurect: 3Q Earnings Snapshot
finance.yahoo.com - November 7 at 5:42 PM
DURECT Corporation Invites You to Join its Third Quarter 2018 Earnings Conference CallDURECT Corporation Invites You to Join its Third Quarter 2018 Earnings Conference Call
finance.yahoo.com - November 1 at 5:56 PM
DURECT Announces Abstracts on DUR-928 to be Presented at Upcoming Scientific MeetingsDURECT Announces Abstracts on DUR-928 to be Presented at Upcoming Scientific Meetings
finance.yahoo.com - October 25 at 8:26 AM
Report: Exploring Fundamental Drivers Behind Alder BioPharmaceuticals, DURECT, Mettler-Toledo International, Internap, Career Education, and Approach Resources — New Horizons, Emerging Trends, and Upcoming DevelopmentsReport: Exploring Fundamental Drivers Behind Alder BioPharmaceuticals, DURECT, Mettler-Toledo International, Internap, Career Education, and Approach Resources — New Horizons, Emerging Trends, and Upcoming Developments
finance.yahoo.com - October 23 at 8:20 AM
Durect In PSC: Is DUR-928 A Class Act?Durect In PSC: Is DUR-928 A Class Act?
seekingalpha.com - October 22 at 5:17 PM
DURECT Corporation appoints Michael H. Arenberg as Chief Financial OfficerDURECT Corporation appoints Michael H. Arenberg as Chief Financial Officer
seekingalpha.com - October 1 at 4:54 PM
DURECT Corporation Appoints Michael H. Arenberg, J.D., M.B.A. as Chief Financial OfficerDURECT Corporation Appoints Michael H. Arenberg, J.D., M.B.A. as Chief Financial Officer
finance.yahoo.com - October 1 at 8:23 AM
DURECT to Present at the Cantor Fitzgerald Global Healthcare ConferenceDURECT to Present at the Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 25 at 8:19 AM
Is DURECT Corporation’s (NASDAQ:DRRX) Balance Sheet Strong Enough To Weather A Storm?Is DURECT Corporation’s (NASDAQ:DRRX) Balance Sheet Strong Enough To Weather A Storm?
finance.yahoo.com - September 19 at 5:38 PM
DURECT +13% on receiving marketing authorization for methydur sustained release capsules for ADHD in TaiwanDURECT +13% on receiving marketing authorization for methydur sustained release capsules for ADHD in Taiwan
seekingalpha.com - September 18 at 4:56 PM
DURECT Announces Methydur Sustained Release Capsules Receive Marketing Authorization for ADHD in TaiwanDURECT Announces Methydur Sustained Release Capsules Receive Marketing Authorization for ADHD in Taiwan
finance.yahoo.com - September 18 at 8:31 AM
DURECT Announces Receipt of $5 Million Milestone Payment from IndiviorDURECT Announces Receipt of $5 Million Milestone Payment from Indivior
finance.yahoo.com - August 30 at 8:33 AM
DURECT to Present at the 20th Annual Rodman & Renshaw Global Investment ConferenceDURECT to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
finance.yahoo.com - August 27 at 5:07 PM
Durect Corporations (DRRX) CEO Jim Brown on Q2 2018 Results - Earnings Call TranscriptDurect Corporation's (DRRX) CEO Jim Brown on Q2 2018 Results - Earnings Call Transcript
seekingalpha.com - August 2 at 5:24 PM
Durect: 2Q Earnings SnapshotDurect: 2Q Earnings Snapshot
finance.yahoo.com - August 2 at 8:28 AM
Edited Transcript of DRRX earnings conference call or presentation 1-Aug-18 8:30pm GMTEdited Transcript of DRRX earnings conference call or presentation 1-Aug-18 8:30pm GMT
finance.yahoo.com - August 2 at 8:28 AM
DURECT Corporation Announces Second Quarter 2018 Financial Results and Provides Corporate UpdateDURECT Corporation Announces Second Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - August 1 at 5:41 PM
Rounds Report: Durect Rallied Due To The FDA Approval Of RBP-7000Rounds Report: Durect Rallied Due To The FDA Approval Of RBP-7000
seekingalpha.com - August 1 at 8:38 AM
DURECT up 16% premarket on FDA OK of Indiviors PercerisDURECT up 16% premarket on FDA OK of Indivior's Perceris
seekingalpha.com - July 30 at 5:14 PM
Why Durect Corporation Stock Is Spiking TodayWhy Durect Corporation Stock Is Spiking Today
www.fool.com - July 30 at 12:25 PM
DURECT Announces FDA Approval of Indiviors PERSERIS™ (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in AdultsDURECT Announces FDA Approval of Indivior's PERSERIS™ (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults
finance.yahoo.com - July 30 at 8:29 AM
DURECT Corporation Invites You to Join its Second Quarter 2018 Earnings Conference CallDURECT Corporation Invites You to Join its Second Quarter 2018 Earnings Conference Call
finance.yahoo.com - July 24 at 4:43 PM
Durect Corporation: What Investors Can Expect From The Upcoming Regulatory BinariesDurect Corporation: What Investors Can Expect From The Upcoming Regulatory Binaries
seekingalpha.com - July 23 at 8:19 AM
Pre-Open Movers 06/27: (DFBG) (CARA) (I) Higher; (AQXP) (PTIE) (DRRX) Lower (more...)Pre-Open Movers 06/27: (DFBG) (CARA) (I) Higher; (AQXP) (PTIE) (DRRX) Lower (more...)
www.streetinsider.com - June 27 at 5:52 PM
Heres Why Drug Developer DURECT Corporation Plunged TodayHere's Why Drug Developer DURECT Corporation Plunged Today
www.msn.com - June 27 at 5:52 PM
Notable Wednesday Option Activity: DRRX, UAA, CLRNotable Wednesday Option Activity: DRRX, UAA, CLR
www.nasdaq.com - June 27 at 5:52 PM
Benzingas Daily Biotech Pulse: Pain Therapeutics Drops 70%, Neon To Begin TradingBenzinga's Daily Biotech Pulse: Pain Therapeutics Drops 70%, Neon To Begin Trading
finance.yahoo.com - June 27 at 5:52 PM
Here's Why Drug Developer DURECT Corporation Plunged TodayHere's Why Drug Developer DURECT Corporation Plunged Today
finance.yahoo.com - June 27 at 5:52 PM
After-Hours Stock Movers 06/26: (DAC) (WWE) Higher; (DRRX) (SONC) (SBLK) Lower (more...)After-Hours Stock Movers 06/26: (DAC) (WWE) Higher; (DRRX) (SONC) (SBLK) Lower (more...)
www.streetinsider.com - June 27 at 9:12 AM
New Research Coverage Highlights Durect, Credit Suisse Group, Obsidian Energy, TransCanada, GoldenNew Research Coverage Highlights Durect, Credit Suisse Group, Obsidian Energy, TransCanada, Golden
www.nasdaq.com - June 7 at 8:21 AM
DURECT Corporation Approaching PDUFA Dates and Analysts ReviewDURECT Corporation Approaching PDUFA Dates and Analysts Review
finance.yahoo.com - June 4 at 8:23 AM
BRIEF-Durect Announces Amendment To Licensing Agreement With SandozBRIEF-Durect Announces Amendment To Licensing Agreement With Sandoz
www.reuters.com - May 10 at 8:30 AM
DURECT up 8% premarket on revised Posimir contract with SandozDURECT up 8% premarket on revised Posimir contract with Sandoz
seekingalpha.com - May 9 at 5:29 PM
Want To Invest In DURECT Corporation (NASDAQ:DRRX)? Here’s How It Performed LatelyWant To Invest In DURECT Corporation (NASDAQ:DRRX)? Here’s How It Performed Lately
finance.yahoo.com - May 8 at 8:23 AM
This page was last updated on 2/21/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel